Skyrizi (Risankizumab) has been recommended for the treatment of severe psoriasis in adults in England and Wales.
The National Institute for Health and Care Excellence (NICE)
has today published its decision to recommend the biologic medicine, Skyrizi
(Risankizumab), to treat severe plaque psoriasis in adults in England and Wales
where the condition has not responded to systemic treatments (such as
methotrexate, ciclosporin and phototherapy), or where these treatments cannot
be tolerated by the patient.
This decision is the result of a fast track appraisal (FTA), a process which was first introduced in 2017 for technologies that offer exceptional value for money. According to NICE, the aim of fast track appraisals is 'to provide quicker access for patients to the most cost-effective new treatments.'
How does Skyrizi
Skyrizi works by blocking the action of interleukin-23
(IL-23), a chemical ‘messenger’ in the immune system which signals other cells
to cause inflammation. In people with psoriasis, the immune system is
overactive and creates too much inflammation, which leads to the development of
psoriasis symptoms. By blocking IL-23, Skyrizi aims to prevent some of that
inflammation from occurring, leading to an improvement in psoriasis for some
people who take it.
How is Skyrizi taken?
Skyrizi is taken by injection at a dose of 150mg (two
injections of 75mg each) at weeks 0
and 4, and every 12 weeks from then on.
We will be publishing more information on Skyrizi in the
near future. If you have any further questions, please get in touch.